Scisparc Submits FDA Investigational New Drug Application for Tourette Syndrome Treatment-February 2024-www.financetom.com

Scisparc Submits FDA Investigational New Drug Application for Tourette Syndrome Treatment

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Scisparc Submits FDA Investigational New Drug Application for Tourette Syndrome Treatment

Sep 22, 2024 4:34 PM

05:10 AM EDT, 09/19/2024 (MT Newswires) -- Scisparc ( SPRC ) said late Wednesday it has submitted an investigational new drug application to the US Food and Drug Administration for a phase 2b trial of SCI-110 as potential treatment of Tourette Syndrome.

The company said it has already secured approvals to test the drug's efficacy, safety and tolerability at sites in the US, Germany and Israel.

Previous page： Desjardins Comments on Canada's GDP Data Next page： HF Sinclair Q3 Adjusted EPS, Revenue Decrease

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Desjardins Comments on Canada's GDP Data

Nov 3, 2024

09:25 AM EDT, 10/31/2024 (MT Newswires) -- Statistics Canada Thursday said that the real gross domestic product likely advanced a heady 0.3% in September, noted Desjardins. That strength was due to gains in finance and insurance, construction, and retail trade. The latter had been a category of concern earlier in the year, with population growth not translating into higher retail...

HF Sinclair Q3 Adjusted EPS, Revenue Decrease

Nov 3, 2024

09:25 AM EDT, 10/31/2024 (MT Newswires) -- HF Sinclair ( DINO ) reported Q3 adjusted earnings Thursday of $0.51 per diluted share, down from $4.06 a year earlier. Analysts polled by Capital IQ expected $0.33. Revenue for the quarter ended Sept. 30 was $7.21 billion, down from $8.91 billion a year earlier. Analysts surveyed by Capital IQ expected $7.11 billion....

Pringles-maker Kellanova beats quarterly sales, profit estimates on steady demand

Nov 3, 2024

(Reuters) - Packaged food company Kellanova ( K ) topped Wall Street estimates for third-quarter sales on Thursday, driven by resilient demand for its ready-to-eat breakfast items and snacks despite rising prices. WHY IT IS IMPORTANT The Cheez-It maker has capitalized on its brand strength to steadily raise product prices over the past few years to strengthen its margins. Higher...

Siemens could reduce stakes in Healthineers, other companies to fund Altair deal

Nov 3, 2024

ZURICH (Reuters) -Siemens could sell off part of its stakes in Siemens Healthineers, Siemens Energy and Fluence to help fund its $10.6 billion Altair acquisition, Chief Financial Officer Ralf Thomas said on Thursday. Siemens currently holds 75% in medical equipment maker Siemens Healthineers and 17% in Siemens Energy, as well as a 31% stake in energy storage company Fluence. We...